Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fate Therapeutics (FATE) Income from Continuing Operations (2016 - 2025)

Fate Therapeutics (FATE) has disclosed Income from Continuing Operations for 14 consecutive years, with 32501000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Income from Continuing Operations rose 43.84% year-over-year to 32501000.0, compared with a TTM value of 136652000.0 through Dec 2025, up 29.19%, and an annual FY2025 reading of 136652000.0, up 29.19% over the prior year.
  • Income from Continuing Operations was 32501000.0 for Q4 2025 at Fate Therapeutics, down from 32160000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 24898000.0 in Q1 2023 and bottomed at 84604000.0 in Q3 2022.
  • Average Income from Continuing Operations over 5 years is 51059700.0, with a median of 46750500.0 recorded in 2023.
  • The sharpest move saw Income from Continuing Operations tumbled 109.01% in 2021, then surged 66.38% in 2023.
  • Year by year, Income from Continuing Operations stood at 69085000.0 in 2021, then grew by 10.92% to 61539000.0 in 2022, then rose by 29.05% to 43661000.0 in 2023, then crashed by 32.55% to 57874000.0 in 2024, then soared by 43.84% to 32501000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for FATE at 32501000.0 in Q4 2025, 32160000.0 in Q3 2025, and 34047000.0 in Q2 2025.